ANI Pharma Reports Positive Phase 4 Trial Results for Iluvien in Non-Infectious Uveitis
Ani Pharmaceuticals (ANIP) announced that its phase 4, open-label study of Iluvien (fluocinolone acetonide intravitreal implant) met both co-primary endpoints in the intent-to-treat population for treating non-infectious uveitis. The trial, named SYNCHRONICITY, showed significant improvements in mean change from baseline across key metrics. The positive results suggest that Iluvien continues to demonstrate efficacy and safety in managing chronic intraocular inflammation associated with non-infectious uveitis. This outcome supports the drug's long-term use as a treatment option for patients who may not respond well to traditional therapies.
Tickers: $ANIP
Topics: Iluvien Pharmaceuticals Uveitis Treatment